Eli Lillys Zepbound set to eclipse Wegovy in U.S. obesity drug market Eli Lillys new obesity drug poised to challenge ...

FDA has ordered specialty pharmacies and online companies to phase out knockoff versions of Eli Lilly's blockbuster drugs ...

Product approvals in regenerative medicine and rare diseases are among the highlights in our recap of recent FDA regulatory decisions.

Stocks are wavering in the early going on Wall Street at the start of a holiday-shortened week. The S&P 500 edged up 0.2% in ...

Ozempic has become a popular wonder drug among many Hollywood celebrities, who turned to the diabetes medication to lose ...

Zepbound was already approved and on the market ... while the Shanghai Composite index slipped 0.5% to 3,351.26. Australia's S&P/ASX 500 jumped 1.7% to 8,201.60. South Korea's Kospi added 1.6 ...

Reuters has earlier reported that two copies of Novo's weight-loss and diabetes drugs, Orsema and Fitaro, had been approved ...

The strategy of buying the 10 highest-yielding stocks in the Dow Jones Industrial Average at the start of the year didn’t pay ...

Following positive feedback from the Australian Competition and Consumer Commission ... earnings expectations whilst fending off concerns that weight-loss drugs like Zepbound may disrupt the sleep ...

Novo Nordisk's Wegovy and Eli Lilly's Zepbound are so far the leaders in ... of time before returning safely to Sydney Airport, the Australian airline said. Qantas plane lands safely in Sydney ...

Five members of the Australian “Bali Nine” drug ring have returned from Indonesia after 19 years in jail following diplomatic efforts between the two countries this month to strike a ...